

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Relay Medical Corp. (the "Issuer").

Trading Symbol: RELA

Number of Outstanding Listed Securities: 135,790,438

Date: September 2, 2020

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

Relay Medical continues to develop and productize multiple products and projects concurrently as well as vet strategic acquisitions that are complimentary to current infrastructure assets. Relay is now concurrently developing the HemoPalm platform and related In Vitro Diagnostics products, Pharmatrac and Osprey Device Networks Corp. (formerly Relay MedNet) as well as the initial development of partially owned subsidiary Glow Lifetech Ltd.

On August 7th, the Company announced a strategic partnership with HaloHealth Angel Network. HaloHealth1 is Canada's first angel network for healthcare and their mission is simple- wanting to help Canada's early stage medical companies succeed and grow by connecting them with domain expertise and capital investment from their physician network. HaloHealth offers live investment pitch events, as well as an online platform to discover potential clinical advisors, novel investment opportunities and several other avenues to connect or collaborate within the HealthTech industry.

On August 19, 2020, Relay announced the establishment of a joint venture ("JV") to accelerate adaption and delivery of Fio's proven data-and-device platform, Fionet, as a COVID-19 pandemic testing, data collection and reporting solution. The JV will operate under the name "Fionet Rapid Response Group" and be headquartered in Toronto, Canada. The Fionet Rapid Response Group will enable mass distributed testing and automated aggregation, triage, and tracking to contain COVID-19, for deployment by public health agencies, retail health providers and private sector companies in Canada, the United States, Europe, Africa, and elsewhere. The combined capabilities of the JV significantly strengthens Fio's ability to rapidly advance and pursue commercial opportunities related to its technology, which has been proven on more than one million cases in over a dozen countries for managing community-based RDT testing, triage, and tracking outbreaks of high-consequence infectious diseases, such as malaria, HIV, dengue, and Ebola, and has been further validated by several dozen publications in scientific journals.

On August 26, 2020, the Company announce the commencement of operations of the Fionet Rapid Response Group ("FRR") to bring a new COVID-19 mobile testing and tracking platform to market. FRR is now in negotiation for trial deployments with several potential partners. The JV operates under the name "Fionet Rapid Response Group" and is headquartered in Toronto, Canada. Fionet is a mobile testing and tracking platform specifically developed for controlled, rapid response to pandemics. The platform combines handheld devices linked to online AI-powered cloud, automating front line testing and capturing test results for tracking. Fionet's rugged, mobile devices are compatible with multiple third-party antigen and antibody COVID-19 rapid diagnostic tests (RDTs), which creates sourcing flexibility for RDTs which are of limited supply and continuously evolving. Fionet also connects with molecular testing devices such as PCRs.

Provide a general overview and discussion of the activities of management.

Management continued to be involved in the development of its business as more specifically detailed in 1 above.

- 2. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.**

See item 1 above.

- 3. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.**

None in the month of August 2020.

- 4. Report on any labour disputes and resolutions of those disputes if applicable.**

None in the month of August 2020.

- 5. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.**

None in the month of August 2020.

- 6. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.**

None in the month of August 2020.

- 7. Provide details of any securities issued and options or warrants granted.**

The Company announced on August 18, 2020 that it has granted an aggregate of 3,600,000 options to purchase common shares of the Company exercisable at \$0.205 per common share and expiring on August 18, 2025, to certain directors, employees, officers and consultants of the Company.

- 8. Provide details of any loans to or by Related Persons.**

Short term advance from a director of \$80,000 with no fixed terms of repayment.

9. Provide details of any changes in directors, officers or committee members.

None in the month of August 2020.

10. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

On March 12, 2020, the World Health Organization ("WHO") declared a global pandemic as a result of the COVID-19 virus. The impacts on global commerce are expected to be far reaching and, at this point, unknown. The global lock-down impacts have negatively impacted the economy as a whole and capital markets in Canada. The effects on the Company's operations have been minor to date but management continues to monitor and contingency plan.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated September 2 2020.

Yoav Raiter

**Name of Director or Senior
Officer**

"Yoav Raiter"

Signature

Chief Executive Officer

Official Capacity

Issuer Details		For Month End	Date of Report
Name of Issuer Relay Medical Corp.		August 31, 2020	YY/MM/D 2020/09/02
Issuer Address 65 International Blvd. Suite 202			
City/Province/Postal Code Toronto, ON M9W 6L9		Issuer Fax No. 1-844-247-6633	Issuer Telephone No. 647-872-9982
Contact Name W. Clark Kent		Contact Position President	Contact Telephone No. 647-872-9982
Contact Email Address ckent@relaymedical.com		Web Site Address https://www.relaymedical.com/	

FORM 7 – MONTHLY PROGRESS REPORT